Comparing the current results to its competitors, Enlivex Therapeutics Ltd reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Enlivex Therapeutics Ltd's competitors' average revenue growth of 34.59 %, achieved in the same quarter.
Enlivex Therapeutics Ltd's Comment on Competition and Industry Peers
The market for osteoarthritis treatment and prevention is highly competitive, with numerous products in development, including FDA-approved therapies specifically for knee osteoarthritis. Competitors encompass large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies, and research institutions. Smaller or early-stage companies may also be significant competitors, particularly through collaborations with larger firms. Competitive factors include efficacy, time of onset, safety, and tolerability profiles.
March 3, 2025
Abstract: Enlivex Therapeutics Ltd. has reported compelling interim results from its Phase I clinical trial of Allocetra, an innovative macrophage reprogramming immunotherapy. This article examines the data from the study, which focuses on the treatment of moderate to severe knee osteoarthritis and highlights the significance of the findings in the context of current treatment paradigms. Knee osteoarthritis (OA) is a chronic degenerative joint disease characterized by persistent pain and reduced mobility, significantly affecting the quality of life in millions of patients globally. Despite the availability of various therapeutic options, the need for more effective treatments remains critical, particularl...
December 5, 2024
On December 5, 2024, Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a pioneering company specializing in macrophage reprogramming immunotherapy, unveiled positive interim efficacy data from the Phase I stage of its Allocetra trial targeting patients with moderate to severe knee osteoarthritis. This trial, which is pivotal for assessing the therapeutic potential of Allocetra, represents a significant advancement in the management of knee osteoarthritis, a condition that affects millions globally and often leads to chronic pain and reduced mobility. Positive Efficacy Data: A Beacon of HopeThe Allocetra trial is a randomized, multi-country Phase I/II study designed to evaluate the safety and efficacy of Allocetra in...
May 29, 2024
Nes-Ziona, Israel May 29, 2024 Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company specializing in macrophage reprogramming, has recently closed a registered direct offering to a single healthcare-focused institutional investor. The offering comprised 3,571,429 ordinary shares and clinical milestone-linked warrants, specifically Series A warrants and Series B warrants to purchase up to 3,571,429 ordinary shares each. These shares were offered at a price of $1.40 per share, culminating in gross proceeds of approximately $5.0 million.This financial injection is significant for Enlivex as it aligns with the company s ongoing efforts to facilitate advanced clinical trials for Al...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Processa Pharmaceuticals Inc is a biopharmaceutical company that operates by developing and commercializing innovative drug candidates for various medical conditions. They focus on advancing treatments through clinical trials, obtaining regulatory approvals, and partnering with other healthcare organizations for distribution and marketing.
Sources:
Enlivex Therapeutics Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Enlivex Therapeutics Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
